Clinical Trial Update: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of gemcitabine and docetaxel with pazopanib for neoadjuvant treatment in soft tissue sarcoma was terminated; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma
• Malignant Peripheral Nerve Sheath Tumor
• Soft Tissue Sarcoma
• Undifferentiated Pleomorphic Sarcoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)
• Pazopanib (Pazopanib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma, Leiomyosarcoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-02-17